EGFR and non-small cell lung carcinoma: Mutations in the gene encoding the epidermal growth factor receptor (<i>EGFR</i>) are common driver mutations in NSCLC that can be effectively targeted by the use of EGFR tyrosine kinase inhibitors (EGFR-TKIs).